SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-1.1
Date Filed: 2025-08-27
Accession Number: 0001213900-25-081175
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025081175/ea025480001ex1-1_synergy.htm

Chunk 2 of 27
Word Count: 1427
Character Count: 9175

Document Content:

good standing with the PCAOB and the PCAOB has not made any determination with respect to the Auditor under the Holding Foreign Companies Accountable Act. The Auditor has not, during the periods covered by the financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act. To the Company’s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus.

(ix) Accounting
and Disclosure Controls. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus,
the Company and its Subsidiaries maintain systems of “internal control over financial reporting” (as defined under
Rules 13a-15 and 15d-15 under the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under
the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access
to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences;
and (v) the interactive data in eXtensible Business Reporting Language included in the Registration Statement, the Time of Sale Disclosure
Package and the Final Prospectus fairly present the information called for in all material respects and are prepared in accordance with
the Commission’s rules and guidelines applicable thereto. Since the date of the latest audited consolidated financial statements
included in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus, there has been no change in the
Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect,
the Company’s internal control over financial reporting. It is understood that this section shall not require the Company to comply
with Section 404 of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the
“Sarbanes-Oxley Act”), as of an earlier date than it would otherwise be required to so comply under applicable law.

Except
as disclosed in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, the Company maintains
disclosure controls and procedures that have been designed to ensure that material information relating to the Company and any Subsidiaries
is made known to the Company’s principal executive officer and principal financial officer by others within those entities; and
such disclosure controls and procedures are effective.

(x) Forward-Looking
Statements. The Company had a reasonable basis for, and made in good faith, each “forward-looking statement” (within the
meaning of Section 27A of the Securities Act or Section 21E of the Exchange Act) contained or incorporated by reference in the Registration
Statement, the Time of Sale Disclosure Package, the Final Prospectus or the Marketing Materials.

(xi) Statistical
and Marketing-Related Data. All statistical or market-related data included in the Registration Statement, the Time of Sale Disclosure
Package or the Final Prospectus, or included in the Marketing Materials, are based on or derived from sources that the Company reasonably
believes to be reliable and accurate, and the Company has obtained the written consent to the use of such data from such sources, to the
extent required.

(xii) Trading Market.
The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is approved for listing on the Nasdaq Capital Market
(“Nasdaq”) subject only to official notice of issuance. To the Company’s knowledge, there is no action pending
by Nasdaq to delist the Common Stock from Nasdaq, nor has the Company received any notification that Nasdaq is contemplating terminating
such listing. When issued, the Shares and the Representative Warrant Shares will be listed on Nasdaq. The Company has taken all actions
it deems reasonably necessary or advisable to take on or prior to the date of this Agreement to assure that it will be in compliance in
all material respects with all applicable corporate governance requirements set forth in the rules of Nasdaq that are then in effect and
will take all action it deems reasonably necessary or advisable to assure that it will be in compliance in all material respects with
other applicable corporate governance requirements set forth in Nasdaq rules not currently in effect upon and all times after the effectiveness
of such requirements.

(xiii) Absence
of Manipulation. The Company has not taken, directly or indirectly, any action that is designed to or that has constituted or that
would reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Shares.

(xiv) Investment
Company Act. The Company is not and, after giving effect to the Offering and sale of the Shares and the application of the net proceeds
thereof, including the proceeds received upon the exercise of the Representative Warrants, will not be an “investment company,”
as such term is defined in the Investment Company Act of 1940, as amended.

(xv) Lock-Up Agreements.
Schedule V hereto contains a complete and accurate list of the Company’s officers and directors (collectively, the “Lock-Up
Parties”). The Company has caused each of the Lock-Up Parties to deliver to the Representative an executed Lock-Up Agreement,
in the form set forth in Exhibit B (the “Lock-Up Agreement”), on or prior to the execution of this Agreement.

(xvi) Integration.
Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated
with prior offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under
the Securities Act.

(xvii) Stabilization.
Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative)
has taken, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to cause or result
in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Shares.

3. Representations and
Warranties Regarding the Company.

(a) The Company represents and
warrants to, and agrees with, the Underwriters, as of the date hereof, as of the Closing Date and as of any Option Closing Date, as follows
(except where a representation and warranty speaks as of a specific date as indicated below):

(i) Good Standing.
Each of the Company and its Subsidiaries has been duly incorporated or organized and is validly existing as a corporation or other entity
in good standing under the laws of its jurisdiction of incorporation. Each of the Company and its Subsidiaries has the power and authority
(corporate or otherwise) to own or lease its properties and conduct its business as currently being carried on and as described in the
Registration Statement, the Time of Sale Disclosure Package and the Prospectus, and is duly qualified to do business as a foreign corporation
or other entity in good standing in each jurisdiction in which it owns or leases real property or in which the conduct of its business
makes such qualification necessary, except where the failure to so qualify would not have or be reasonably likely to result in a material
adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the
Company and its Subsidiaries, taken as a whole, or in its ability to perform its obligations under this Agreement (“Material
Adverse Effect”).